Intrusion Inc. — 2015 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2015, Intrusion developed and sold cybersecurity and data-analysis products, principally TraceCop (entity identification) and Savant (network data mining and threat detection). Sales were predominantly domestic and heavily reliant on U.S. government customers. The company had 36 full-time employees at year-end.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $6.824 million | $7.219 million |
| Gross profit / margin | $4.294 million / 62.9% | $4.687 million / 64.9% |
| Operating loss | $1.142 million | $221,000 |
| Net loss | $1.249 million | $274,000 |
| Net loss attributable to common stockholders | $1.388 million | $415,000 |
| Cash from (used in) operations | $(638,000) | $571,000 |
| Cash and cash equivalents at year-end | $102,000 | $1.006 million |
| Working capital | $(787,000), approximately | $391,000, approximately |
Revenue declined 5.5%; net product revenue fell about 5.0%, while customer support and maintenance revenue fell 58% to $29,000, largely due to expiring Compliance Commander maintenance contracts. Operating expenses rose overall, particularly research and development and sales and marketing. R&D spending was $2.315 million, up from $1.941 million. Interest expense was $107,000 in both years; the 2014 results included $54,000 of other income. No income tax provision was recorded, as deferred tax assets were fully offset by a valuation allowance.
Operating cash flow swung to an outflow of $638,000. Investing activities used $121,000, mainly for equipment, and financing activities used $145,000, primarily for capital-lease principal payments. There were no borrowings outstanding on the SVB line at year-end. The company had $1.530 million outstanding under its unsecured revolving loan from CEO G. Ward Paxton, plus $76,500 of accrued interest. The SVB facility had a $625,000 stated limit and a $380,000 year-end borrowing base; it was secured by substantially all company assets, including intellectual property. Capital-lease obligations totaled $336,000 on the balance sheet, with $355,000 of future payments disclosed.
Material changes and management outlook
- Net loss widened to $1.249 million from $274,000, and cash fell by $904,000 during 2015.
- Management attributed lower revenue to slower-than-expected growth in TraceCop and Savant sales. It said gross margin was pressured by lower product sales and mix.
- U.S. government sales rose to 54.7% of revenue from 51.4%; three government customers together represented approximately 43.9% of 2015 revenue.
- Management expected product revenue to increase as market acceptance of TraceCop and Savant improves, and expected sales and marketing, R&D, and G&A expenses to rise as revenue grows. No specific revenue or earnings guidance was provided.
- Management believed available cash, borrowing capacity, anticipated profits, and CEO financing would fund operations and expected capital expenditures for the next 12 months. This outlook depends on projected revenue and net-income growth; the filing warns that inadequate cash flow or unavailable financing could impair operations or threaten business continuity.
- The CEO loan was renewed in February 2016 on the same revolving terms, with borrowing permitted up to $2.2 million through March 2018. The SVB facility was due to terminate June 21, 2016; the company said it expected to renew it.
Risks, contingencies, and unusual items
- Preferred dividends continue to accrue: $160,000 was payable at year-end, and unpaid dividends may consume scarce cash. Certain preferred holders may have redemption rights; the filing describes potential cash-redemption and substantial share-dilution exposure under specified circumstances.
- Government purchasing and budget decisions, contract cancellations, long sales cycles, and concentration in a small number of customers could materially affect revenue.
- Indirect channels accounted for 74.7% of revenue in 2015, increasing dependence on distributors, resellers, integrators, and other partners.
- The company reported an accumulated deficit of $59.947 million. Additional financing may be needed and could be unavailable or dilutive; preferred securities and outstanding options also create dilution risk.
- Competition, evolving technology, product acceptance, cybersecurity vulnerabilities, intellectual-property claims, and supplier availability pose additional risks. Ordinary-course legal proceedings were disclosed; management did not believe any were likely to have a material adverse effect.
- Management concluded disclosure controls and internal control over financial reporting were effective. The auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether the company restored operating cash flow and maintained adequate liquidity after year-end, including actual use and renewal of the SVB facility and CEO loan.
- Whether TraceCop and Savant sales improved enough to offset ongoing losses and increased operating expenses.
- Whether government-customer concentration and indirect-channel dependence changed, and whether any significant contracts were cancelled or delayed.
- The status and cash impact of accrued preferred dividends, potential redemption rights, and dilution from preferred stock and options.
- Reconcile the filing’s margin disclosures: the audited statements show 2014 gross margin of 64.9%, while MD&A elsewhere cites 64.7% for product margin; these are different measures, and the distinction should be checked against the underlying statements.